Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1
/in Dendritic Cells, Glioblastoma, International PublicationsCombined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
/in Dendritic Cells, Glioblastoma, International PublicationsThe current state of immunotherapy for gliomas: an eye toward the future
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusGlycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
/in Dendritic Cells, Exosome, Glioblastoma, International PublicationsSafety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsA Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
/in Dendritic Cells, Glioblastoma, International PublicationsImmune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
/in Glioblastoma, International Publications, IOZK VeröffentlichungenAn effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma
/in Dendritic Cells, Glioblastoma, International PublicationsEffective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer